Format

Send to:

Choose Destination
See comment in PubMed Commons below
Dement Geriatr Cogn Dis Extra. 2013 May 1;3(1):143-7. doi: 10.1159/000350029. Print 2013 Jan.

The Effect of Solifenacin on Cognitive Function following Stroke.

Author information

  • 1Department of Physical Medicine and Rehabilitation, Dongguk University Ilsan Hospital, Goyang-si, Republic of Korea.

Abstract

BACKGROUND/AIMS:

Our aim was to investigate the effect of solifenacin (an anticholinergic) on cognitive function after stroke.

METHODS:

We retrospectively reviewed 66 stroke cases who were prescribed solifenacin for more than 2 months. A control group was generated matching the patients both for sex and age. The interval changes in the Mini-Mental State Examination (MMSE) score and Clinical Dementia Rating Sum of Boxes (CDR-SB) score after solifenacin administration were compared to those of the control group.

RESULTS:

The baseline MMSE score of the control group was 15.9 ± 9.2 and that of the solifenacin group was 14.3 ± 7.8. After using solifenacin for an average of 76.9 days, there was a change in the MMSE score of 1.9 ± 5.2. During similar periods, there was a change in the MMSE score of 2.9 ± 3.7 in the control group (not using solifenacin). However, there was no significant difference between the two groups. Similarly, there was no significant difference in the CDR-SB score between the two groups.

CONCLUSION:

Solifenacin treatment did not affect the short-term cognitive performance in stroke patients. This information might be useful when prescribing anticholinergics to stroke patients.

KEYWORDS:

Anticholinergics; Cognitive symptoms; Muscarinic receptors; Solifenacin; Stroke

PMID:
23687509
[PubMed]
PMCID:
PMC3656674
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
    Loading ...
    Write to the Help Desk